Pharmacokinetics of oral mycophenolate mofetil in volunteer subjects with varying degrees of hepatic oxidative impairment

Journal of Clinical Pharmacology

Volumn 36, Issue 4, 1996, Pages 332-344

  Parker, Gerry ^a   Bullingham, Roy ^a,b   Kamm, Barbara ^a   Hale, Michael ^a  

^a Roche Global Development   (United States)

^b Roche Global Development Palo Alto   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPHENAZONE; CREATININE; DRUG METABOLITE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ADULT; ALCOHOL LIVER CIRRHOSIS; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTICLE; BREATH ANALYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG URINE LEVEL; HUMAN; LIVER METABOLISM; MALE; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS;

EID: 0029865220     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1996.tb04209.x     Document Type: Article

References (10)

1. Eugui EM, Almquist SJ, Muller CD, Allison AC: Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991;3:161-173.
2. Bullingham RES, Nicholls A, Hale M: Pharmacokinetics of mycophenolate mofetil (RS 61443): a short review. Transplant Proc 1996;28:935-939.
3. 14C] aminopyrine in liver diseases. Dig Dis Sci 1982;27:49-56.
4. Albers I, Hartmann H, Bircher J, Creutzfeldt W: Superiority of the Child-Pugh classification to quantitative liver function tests for assessing prognosis of liver cirrhosis. Scand J Gastroenterol 1989;24:269-276.
5. Tsina I, Chu F, Hama K, Kaloostian M, Tam YL, Tarnowski T, Wong B: Manual and automated (robotic) high-performance liquid chromatography methods for the determination of mycophenolic acid and its glucuronide conjugate in human plasma. J Chromatogr B Biomed App; 1996;675:119-129.
6. Bullingham R, Monroe S, Nicholls A, Hale M: Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. J Clin Pharmacol 1996;36:315-324.
7. Nowak I, Shaw LM: Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995;7:1011-1017.
8. Luke DR, Halstenson CE, Opsahl JA, Matzke GR: Validity of creatinine clearance estimates in the assessment of renal function. Clin Pharmacol Ther 1990;48:503-508.
9. Kroemer HK, Klotz U: Glucuronidation of drugs. Clin Pharmacokinet 1992;23:292-310.
10. Nicholls AJ, Bullingham RES, Parker G, Hale MD: Interaction of oral mycophenolate mofetil with cholestyramine: evidence for enterohepatic circulation of mycophenolic acid. Clin Pharmacol Ther (submitted for publication).